| Authors | Therapy | Phase | Type of Cancer | Olaparib Dose | No. of Patients(No. with BRCAm BC) | MTD (dose finding trails only) | Objective ResponseResults in BRCAm cohorts |
|---|---|---|---|---|---|---|---|
| Fong, 2009 | Olaparib | 1 | Solid tumours | 10-600 BID | 60 (3) | 400 mg BID | 33% |
| Tutt, 2010 | Olaparib | 2 | BRCAm breast cancer | 400 or 100 BID | 54 (54) | — | 41% at 400 mg BID, 22% at 100 mg BID |
| Gelmon, 2011 | Olaparib | 2 | BRCAm breast cancer and ovarian cancer | 400 BID | 90 (10) | — | 0% |
| Balmana, 2014 | Olaparib plus Cisplatin | 1 | Breast, ovarian, pancreatic, peritoneal cancers | 50-200 BID (continuous and intermittent dosing schedules) | 53 (17) | cisplatin 60 mg/m2 with intermittent olaparib 50 mg BID deemed tolerable but MTD not reached | 71% |
| Lee, 2014 | Olaparib plus Carboplatin | 1/1b | BRCAm breast cancer and ovarian cancer | 100-400 BID (continuous and intermittent dosing schedules) | 45 (8) | carboplatin AUC 5 with intermittent olaparib 400 mg BID was highest tested dose but MTD not reached | 87.5% |
| Kaufman, 2015 | Olaparib | 2 | Various BRCAm cancers | 400 BID | 317 (62) | — | 12.9% |
| Robson, 2017 | Olaparib | 3 | BRCAm breast cancer | 300 BID | 302 (302) | — | 59.9% |